Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Combined with the last dividend raise by +3.3% in December 2024, building upon the 10Y growth profile at +5.27%, we believe ...

Options Corner: Political Turmoil Sets Up A Contrarian Call Spread For Bristol-Myers Squibb Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos ...

Bristol Myers BMY announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) ...

Top 5 S&P 500 healthcare performers in Q3: Bristol-Myers Squibb (BMY) +30.78% Solventum (SOLV) +30.43% HCA Healthcare (HCA) +26.82% ResMed (RMD) +26.09% Waters Corporation (WAT) +25.96% Bristol ...

Let's delve deeper into each type of owner of Bristol-Myers Squibb, beginning with the chart below. Many institutions measure their performance against an index that approximates the local market.